Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Augmentation Clear all
Completed Phase 2 Interventional Results available

Phase 2B Upper Extremity Nerve Block Study

NCT03011333
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Bupivacaine HCl without epinephrine, Saline Placebo
Drug
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Pasadena, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Minocycline Augmentation to Clozapine

NCT02124811
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Minocycline
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Effectiveness and Safety of Belotero Balance® (+) Lidocaine for Volume Augmentation of the Infraorbital Hollow

NCT04594239
View directory record Official record
Conditions
Volume Loss in the Infraorbital Hollow Area
Interventions
Belotero Balance (+) Lidocaine, needle, Belotero Balance (+) Lidocaine, cannula, Untreated-control / delayed-treatment, needle, Untreated-control / delayed-treatment, cannulas
Device
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Solana Beach, California • Vista, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

D-serine Augmentation of Neuroplasticity

NCT03711500
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder
Interventions
D-serine, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)

NCT02155829
View directory record Official record
Conditions
PTSD
Interventions
Riluzole, Placebo (for Riluzole)
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

NCT04414930
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
d-amphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Not applicable Interventional Results available

Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD

NCT02012452
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Tobacco Dependence
Interventions
Tobacco treatment, Health Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 30, 2026, 10:57 AM EDT
Recruiting Not applicable Interventional

Carpal Arch Space Augmentation (CASA) Clinical Trial

NCT06208709
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
carpal arch space augmentation (CASA), standard of care (SOC)
Device
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Pimozide Augmentation for Clozapine Partial Response

NCT00374244
View directory record Official record
Conditions
Schizophrenia
Interventions
Pimozide, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

NCT02977299
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Recruiting No phase listed Observational

BioBrace® Augmentation in Anterior Cruciate Ligament Reconstruction Procedures

NCT06948591
View directory record Official record
Conditions
ACL Tears
Interventions
Anterior cruciate ligament reconstruction with BioBrace® augmentation, Arthroscopic anterior cruciate ligament reconstruction
Device · Procedure
Lead sponsor
CONMED Corporation
Industry
Eligibility
14 Years to 70 Years
Enrollment
500 participants
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Restylane Lyft With Lidocaine for Augmentation of the Chin Region to Improve the Chin Profile

NCT05777759
View directory record Official record
Conditions
Chin Augmentation, Chin Retrusion
Interventions
Restylane Lyft with Lidocaine, Juvederm Voluma XC
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
11
States / cities
Los Angeles, California • Manhattan Beach, California • Westport, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Investigation of Macular Pigment Augmentation on Dark Adaptation

NCT00478439
View directory record Official record
Conditions
Aging, Age-Related Macular Degeneration
Interventions
ZeaVision EyePromise Restore, Multivitamin
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 27, 2010 · Synced Oct 30, 2026, 10:57 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Bio ACL Reconstruction Amnion Collagen Matrix Wrap and Stem Cells

NCT03294759
View directory record Official record
Conditions
ACL - Anterior Cruciate Ligament Rupture
Interventions
Bio ACL, Control
Other
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 30, 2026, 10:57 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

NCT06320951
View directory record Official record
Conditions
Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Energy Expenditure, Obesity
Interventions
Vericiguat 10 MG, Placebo, Insulin Sensitivity Test, Resting Energy and Exercise Energy Expenditure Assessment, White Adipose Tissue Biopsy, MRI-PET Scan for Brown Adipose Tissue Volume Assessment
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation

NCT03160716
View directory record Official record
Conditions
Cheek Augmentation, Midface Contour Deficiencies
Interventions
Restylane Lyft with Lidocaine
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 30, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation

NCT00813111
View directory record Official record
Conditions
Pain
Interventions
SKY0402, Bupivacaine HCl
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 30, 2026, 10:57 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Calcium Carbonate to Augment Labor Contractions

NCT06580782
View directory record Official record
Conditions
Labor Dystocia, Labor Induction, Labor Augmentation
Interventions
Calcium Carbonate 500 MG, Standard Dose Synthetic Pitocin
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of Juvéderm® VOLUMA XC Injectable Gel for Cheek Augmentation

NCT00978042
View directory record Official record
Conditions
Mid-facial Volume Deficit Related to Aging
Interventions
Juvéderm® VOLUMA XC
Device
Lead sponsor
Allergan
Industry
Eligibility
35 Years to 65 Years
Enrollment
345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 30, 2026, 10:57 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Clinical and Histological Evaluation of Healos® for Alveolar Ridge Augmentation

NCT01154868
View directory record Official record
Conditions
Dental Implantation
Interventions
Alveolar ridge augmentation
Procedure
Lead sponsor
William Giannobile
Other
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Parent Emotion Coaching for Anorexia Nervosa

NCT04421989
View directory record Official record
Conditions
Anorexia Nervosa, Atypical Anorexia Nervosa
Interventions
Emotion Coaching, Support Group
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 30, 2026, 10:57 AM EDT
Completed Not applicable Interventional Results available

D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

NCT00963924
View directory record Official record
Conditions
Schizophrenia
Interventions
D-cycloserine, Placebo, Cognitive Remediation
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 30, 2026, 10:57 AM EDT